SEHK:3696Life Sciences
InSilico Medicine Deepens AI Drug Development With Qilu And ISM8969 Shift
InSilico Medicine Cayman TopCo (SEHK:3696) has agreed a major partnership with Qilu Pharmaceutical to co-develop small molecule drugs for cardiometabolic diseases using its Pharma.AI platform.
The company is also reporting progress and fresh licensing activity around its ISM8969 program, which targets neurodegenerative disorders.
Together, these updates mark a shift from a primarily software licensing approach toward more hands-on, co-development work in drug discovery.
For you as an...